This technology is a fast-acting dual-agonist that simultaneously activates μ-opioid receptor and nociceptin receptor, exhibiting high safety. It rapidly activates μ-opioid receptor to effectively relief pain. Additionally, it can reduce drug tolerance, enhance safety, and alleviate constipation by activating nociceptin receptor. The promotion of this technology will be facilitated through the postoperative pain market.

• Compared to morphine (traditional analgesic):
 - Demonstrates faster onset and superior antinociception.
 - Exhibits reduced constipation, antinociceptive tolerance, and withdrawal symptoms.
 • Compared to Oliceridine (Olynvik) for post-operative pain:
 - Demonstrates faster onset and stronger antinociception.
 - Exhibits fewer withdrawal symptoms.
 - Offers simpler and more cost-effective manufacturing.

• Innovation: Novel small molecule MOR/NOP dual agonist providing rapid pain relief.
 • Safety Advantage: No hematological or biochemical toxicity, minimal gastrointestinal effects, and absence of tolerance development.
 • Market Positioning: Best-in-class small molecule MOR/NOP dual agonist analgesic.
 • IP Protection: Robust global patent protection for compound composition.